<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332692</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A03311-56</org_study_id>
    <nct_id>NCT04332692</nct_id>
  </id_info>
  <brief_title>Acute Heart Failure - COngestion Discharge Evaluation</brief_title>
  <acronym>AHF-CODE</acronym>
  <official_title>Acute Heart Failure - COngestion Discharge Evaluation. Évaluation de la Congestion à la Sortie d'Hospitalisation Pour Insuffisance Cardiaque aiguë.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute heart failure (AHF) is a major public health problem, associated with a 40% risk of
      death or re-hospitalisation at 3 months. This risk is significantly increased by insufficient
      decongestion at the end of hospitalisation for AHF assessed by a standardised clinical score,
      a natriuretic peptide dosage or by cardiac and pulmonary ultrasound .

      Adapting treatment according to lung congestion assessed by implantable devices (not
      reimbursed in France) improves the prognosis. However, due to the lack of a standardised
      congestion assessment, therapeutic adaptation in acute heart failure is currently empirical.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">May 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>composite endpoint : rate of death from all causes or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of re-hospitalisation for acute heart failure</measure>
    <time_frame>3 months after hospital discharge</time_frame>
    <description>composite endpoint : rate of death from all causes or re-hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>3 and 12 months after hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of re-hospitalisation for acute heart failure</measure>
    <time_frame>3 and 12 months after hospital discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>12 months after hospital discharge</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure at 12 months after hospital discharge (with outcome 6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisation for acute heart failure</measure>
    <time_frame>12 months after hospital discharge.</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure at 12 months after hospital discharge (with outcome 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>3 months after hospital discharge.</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisation for acute heart failure</measure>
    <time_frame>3 months after hospital discharge.</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure at 3 months after hospital discharge (with outcome 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA (New York Heart Association) class measured</measure>
    <time_frame>3 and 12 months after hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natriuretic peptides</measure>
    <time_frame>within 12 months after hospital discharge.</time_frame>
    <description>BNP or Nt-Pro BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function assessed by glomerular filtration rate</measure>
    <time_frame>within 12 months after hospital discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma volume</measure>
    <time_frame>within 12 months after hospital discharge.</time_frame>
    <description>calculated from haemoglobin and haematocrit value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood potassium</measure>
    <time_frame>within 12 months after hospital discharge.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients hospitalized for acute heart failure will undergo the following evaluations:
Clinical examination focusing on congestion
Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds
Blood sample retrieved for biological assessment and biobanking
Telephone follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clinical examination centered on congestion</intervention_name>
    <description>Clinical examination centered on congestion will be performed before discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds</intervention_name>
    <description>Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds will be performed before discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample retrieved for biological assessment and biobanking</intervention_name>
    <description>Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Telephone follow-up</intervention_name>
    <description>Telephone follow-up will be performed 3 months and 12 months after discharge from hospital</description>
    <arm_group_label>Patients hospitalized for acute heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalised for acute heart failure.

          -  Patients considered clinically discharging from hospitalisation for acute heart
             failure.

          -  Age ≥18 years

          -  Patients having received complete information regarding the study design and having
             signed their informed consent form.

          -  Patient affiliated to or beneficiary of a social security scheme.

        Exclusion Criteria:

          -  Comorbidity for which the life expectancy is ≤ 3 months

          -  Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular
             filtration rate &lt;15 ml/min/m2 at inclusion.

          -  History of lobectomy or pneumonectomy lung surgery

          -  Severe pulmonary or pleural pathology preventing reliable acquisition of lung
             ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.

          -  Valvulopathy causing decompensation of heart failure for which intervention is being
             considered.

          -  Pregnant woman, parturient or nursing mother

          -  Adult person subject to a legal protection measure (guardianship, curatorship,
             safeguard of justice)

          -  Adult person who is unable to give consent

          -  Person deprived of liberty by a judicial or administrative decision,

          -  Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the
             Public Health Code.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas GIRERD, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU of Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas GIRERD, MD,PhD</last_name>
    <phone>+ 33 3 83 15 73 22</phone>
    <phone_ext>+ 33 3</phone_ext>
    <email>n.girerd@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanae BOUALI, PhD</last_name>
    <phone>+ 33 3 83 15 73 22</phone>
    <phone_ext>+ 33 3</phone_ext>
    <email>s.bouali@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas GIRERD, MD, PhD</last_name>
      <phone>+33383157322</phone>
      <phone_ext>+333</phone_ext>
      <email>n.girerd@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

